One of the hypotheses of the pathophysiology of major depressive disorder (MDD) proposes that there is a relationship between adipocytokine and ghrelin levels and depression.
Methods:
Patients with major depression with a BMI ≤25 kg/m2 between the ages of 11 and 18 years (n = 30) were compared with a healthy control group (n = 30). Both groups were evaluated across a pretreatment period (MD-PT) and an improved period (MD-I). We measured serum leptin, adiponectin, resistin, and ghrelin levels and other parameters related to metabolic syndrome, such as glucose, insulin, insulin resistance (homeostasis model assessment [HOMA]), triglycerides (TG), and total cholesterol (TCHOL).
Results:
Leptin, adiponectin, and resistin levels did not differ across groups; however, ghrelin levels were increased in the MD-I group compared with the control and MD-PT groups (p < 0.05). HOMA levels were also higher in the MD-PT group than in the control group (p < 0.05). After treatment, there was no difference in this measurement.
Conclusions:
The relationship between adipocytokines and major depression may be dependent on ghrelin levels as a result of antidepressant treatment and subsequent obesity.
Get full access to this article
View all access options for this article.
References
1.
AbizaidA, LiuZW, AndrewsZB, ShanabroughM, BorokE, ElsworthJD, RothRH, SleemanMW, PicciottoMR, TschöpMH, GaoXB, HorvathTL: Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest, 116:3229–3239, 2006.
2.
AntonijevicIA, MurckH, FrieboesRM, HornR, BrabantG, SteigerA: Elevated nocturnal profiles of serum leptin in patients with depression. J Psychiatr Res, 32:403–410, 1998.
3.
AustinAW, GordonJL, LavoieKL, ArsenaultA, DasguptaK, BaconSL: Differential association of insulin resistance with cognitive and somatic symptoms of depression. Diabet Med, 31:994–1000, 2014.
4.
BarimAO, AydinS, ColakR, DagE, DenizO, SahinI: Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment. Clin Biochem, 42:1076–1081, 2009.
5.
BokarewaM, NagaevI, DahlbergL, SmithU, TarkowskiA: Resistin, an adipokine with potent proinflammatory properties. J Immunol, 174:5789–5795, 2005.
6.
CarvalhoAF, RochaDQC, McIntyreRS, MesquitaLM, KohlerCA, HyphantisT N, SalesPMG, Machado–VieiraR, BerkM: Adipokines as emerging depression biomarkers: A systematic review and meta-analysis. J Psychiatr Res, 59:28–37, 2014.
7.
CascadeE, KalaliAH, KennedySH: Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont), 6:16–18, 2009.
CizzaG, NguyenVT, EskandariF, DuanZ, WrightEC, ReynoldsJC, AhimaRS, BlackmanMR: Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: The Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. J Clin Psychiatry, 71:1079–1087, 2010.
10.
CizzaG, RonsavilleDS, KleitzH, EskandariF, MistryS, TorvikS, SonbolianN, ReynoldsJC, BlackmanMR, GoldPW, MartinezPE: Clinical subtypes of depression are associated with specific metabolic parameters and circadian endocrine profiles in women. PloS One, 7:e28912, 2012.
11.
DeuschleM, BlumWF, EnglaroP, SchweigerU, WeberB, PflaumCD, HeuserI: Plasma leptin in depressed patients and healthy controls. Horm Metab Res, 28:714–717, 1996.
12.
DinizBS, TeixeiraAL, CamposAC, MirandaAS, RochaNP, TalibLL, GattazWF, ForlenzaOV: Reduced serum levels of adiponectin in elderly patients with major depression. J Psychiatr Res, 46:1081–1085, 2012.
13.
DowlatiY, HerrmannN, SwardfagerW, LiuH, ShamL, ReimEK, LanctôtKL: A meta analysis of cytokines in major depression. Biol Psychiatry, 67:446–457, 2010.
14.
EmülHM, SerteserM, KurtE, OzbulutO, GulerO, GeciciO: Ghrelin and leptin levels in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry, 31:1270–1274, 2007.
15.
Ferńandez–RealJM, Ĺopez–BermejoA, CasamitjanaR, RicartW: Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab, 88:2714–2718, 2003.
16.
FragoLM, BaquedanoE, ArgenteJ, ChowenJA: Neuroprotective actions of ghrelin and growth hormone secretagogues. Front Mol Neurosci, 4:23, 2011.
17.
GöklerB, ÜnalF, PehlivantürkB, KültürEÇ, AkdemirD, TanerY: Reliability and validity of Schedule for Affective Disorders and Schizophrenia for School Age Children–Present and Lifetime Version–Turkish Version (K-SADS-PL-T) [in Turkish]. Turk J Child Adolesc Ment Health, 11:109–116, 2004.
18.
HeiskanenTH, NiskanenLK, HintikkaJJ, Koivumaa–HonkanenHT, HonkalampiKM, HaatainenKM, ViinamäkiHT: Metabolic syndrome and depression: A cross–sectional analysis. J Clin Psychiatry, 67:1422–1427, 2006.
IshitobiY, KohnoK, KanehisaM, InoueA, ImanagaJ, MaruyamaY, NinomiyaT, HigumaH, OkamotoS, TanakaY, TsuruJ, HanadaH, IsogawaK, AkiyoshiJ: Serum ghrelin levels and the effects of antidepressants in major depressive disorder and panic disorder. Neuropsychobiology, 66:185–192, 2012.
21.
JowGM, YangTT, ChenCL: Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord, 90:21–27, 2006.
22.
KlugeM, SchusslerP, SchmidD, UhrM, KleyerS, YassouridisA, SteigerA: Ghrelin plasma levels are not altered in majordepression. Neuropsychobiology, 59:199–204, 2009.
23.
KnolMJ, TwistJW, BeekamAT, HeineRJ, HeineRJ, SnoekFJ, PowerF: Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis Diabetologia, 49:837–845, 2006.
24.
KojimaM, HosodaH, DateY, NakazatoM, MatsuoH, KangawaK: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402:656–660, 1999.
25.
KotanZ, SarandolE, KirhanE, OzkayaG, KirliS: Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features. Ther Adv Psychopharmacol, 2:65–74, 2012.
26.
KrausT, HaackM, SchuldA, Hinze–SelchD, PollmächerT: Low leptin levels but normal body mass indices in patients with depression or schizophrenia. Neuroendocrinology, 73:243–247, 2001.
27.
KumarJ, ChuangJC, NaES, KupermanA, GillmanAG, MukherjeeS, ZigmanJM, McClungCA, LutterM: Differential effects of chronic social stress and fluoxetine on meal patterns in mice. Appetite, 64:81–88, 2013.
28.
KwonH, PessinJE: Adipokines mediate inflammation and insulin resistance. Front Endocrinol, 4:71, 2013.
29.
LangUE, BorgwardtS: Molecular mechanisms of depression: Perspectives on new treatment strategies. Cell Physiol Biochem, 31:761–777, 2013.
30.
LehtoSM, HuotariA, NiskanenL, TolmunenT, Koivumaa–HonkanenH, HonkalampiK, RuotsalainenH, HerzigKH, ViinamäkiH, HintikkaJ: Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand, 121:209–215, 2010.
31.
LeoR, Di LorenzoG, TesauroM, ColaC, FortunaE, ZanasiM, TroisiA, SiracusanoA, LauroR, RomeoF: Decreased plasma adiponectin concentration in major depression. Neurosci Lett, 407:211–213, 2006.
32.
LiuJ, GuoM, ZhangD, ChengSY, LiuM, DingJ, SchererPE, LiuF, LuXY: Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant–like activity. Proc Natl Acad Sci U S A, 109:12,248–12,253, 2012.
33.
LuppinoFS, de WitLM, BouvyPF, StijnenT, CuijpersP, PenninxBW, ZitmanFG: Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry, 67:220–229, 2010.
34.
LutterM, SakataI, Osborne–LawrenceS, RovinskySA, AndersonJG, JungS, BirnbaumS, YanagisawaM, ElmquistJK, NestlerEJ, ZigmanJM: The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci, 11:752–753, 2008.
35.
MarazzitiD, RutiglianoG, BaroniS., LandiP, Dell'OssoL: Metabolic syndrome and major depression. CNS Spectr, 19:293–304, 2014.
36.
MatsuoK, NakanoM, NakashimaM, WatanukiT, EgashiraK, MatsubaraT, WatanabeY: Neural correlates of plasma acylated ghrelin level in individuals with major depressive disorder. Brain Res, 1473:185–192, 2012.
37.
MilaneschiY, SutinAR, TerraccianoA, CanepaM, GravensteinKS, EganJM, VogelzangsN, GuralnikJM, BandinelliS, PenninxBW, FerrucciL: The association between leptin and depressive symptoms is modulated by abdominal adiposity. Psychoneuroendocrinology, 42:1–10, 2014.
38.
MorrisAA, AhmedY, StoyanovaN, HooperWC, De StaerkeC, GibbonsG, QuyyumiA, VaccarinoV: The association between depression and leptin is mediated by adiposity. Psychosom Med, 74:483–488, 2012.
39.
Nieto–VazquezI, Fernandez–VeledoS, KramerD K, Vila–BedmarR, Garcia–GuerraL, LorenzoM: Insulin resistance associated to obesity: The link TNF-alpha. Arch Physiol Biochem, 114:183–194, 2008.
40.
OsbyU, BrandtL, CorreiaN, EkbomA, SparenP: Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry, 58:844–850, 2001.
41.
OuchiN, ParkerJL, LugusJJ, WalshK: Adipokines in inflammation and metabolic disease. Nat Rev Immunol, 11:85–97, 2011.
42.
PanA, YeX, FrancoOH, LiH, YuZ, WangJ, QiQ, GuW, PangX, LiuH, LinX: The association of depressive symptoms with inflammatory factors and adipokines in middle-aged and older Chinese. Plos One, 3:e1392, 2008.
43.
PapakostasGI, SheltonRC, KinrysG, HenryME, BakowBR, LipkinSH, PiB, ThurmondL, BilelloJA: Assessment of a multiassay, serum-based biological diagnostic test for major depressive disorder: A pilot and replication study. Mol Psychiatry, 18:332–329, 2013.
44.
PascoJA, JackaFN, WilliamsLJ, HenryMJ, NicholsonGC, KotowiczMA, BerkM: Leptin in depressed women: Cross-sectional and longitudinal data from an epidemiologic study. J Affect Disord, 107:221–225, 2008.
45.
PaslakisG, WestphalS, HamannB, GillesM, LederbogenF, DeuschleM: Unstimulated and glucose-stimulated ghrelin in depressed patients and controls. J Psychopharmacol, 28:582–586, 2014.
46.
PatelSD, RajalaMW, RossettiL, SchererPE, ShapiroL: Disulfide-dependent multimeric assembly of resistin family hormones. Science, 304:1154–1158, 2004.
47.
PineDS, CohenP, BrookJ, CoplanJD: Psychiatric symptoms in adolescence as predictors of obesity in early adulthood: A longitudinal study. Am J Public Health, 87:1303–1310, 1997.
48.
RobertsRE, DelegerS, StrawbridgeWJ, KaplanGA: Prospective association between obesity and depression: evidence from the Alameda County Study. Int J Obes Relat Metab Disord, 27: 514–521, 2003.
49.
RubinRT, RhodesME, CzambelRK: Sexual diergism of baseline plasma leptin and leptin suppression by arginine vasopressin in major depressives and matched controls. Psychiatry Res, 113:255–268, 2002.
50.
RyoM, NakamuraT, KiharaS, KumadaM, ShibazakiS, TakahashiM, NagaiM, MatsuzawaY, FunahashiT: Adiponectin as a biomarker of the metabolic syndrome. Circ J, 68:975–981, 2004.
51.
ShinAC, ZhengH, BerthoudHR: An expanded view of energy homeostasis: Neural integration of metabolic, cognitive and emotional drives to eat. Physiol Behav, 97:572–580, 2009.
52.
SimonGE, Von KorffM, SaundersK, MigliorettiDL, CranePK, van BelleG, KesslerRC: Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry, 63:824–830, 2006.
53.
SoczynskaJK, KennedySH, WoldeyohannesHO, LiauwSS, AlsuwaidanM, YimCY, McIntyreRS: Mood disorders and obesity: Understanding inflammation as a pathophysiological nexus. Neuromol Med, 13:93–116, 2011.
54.
SteppanCM, BaileyST, BhatS, BrownEJ, BanerjeeRR, WrightCM, PatelHR, AhimaRS, LazarMA: The hormone resistin links obesity to diabetes. Nature, 409:307–312, 2001.
55.
SussmanN, GinsbergDL, BikoffJ: Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry, 62:256–260, 2001.
56.
TaylorVH, MacQueenGM: The role of adipokines in understanding the associations between obesity and depression. J Obes, 2010:748048, 2010.
57.
TeixeiraPJ, RochaFL: The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr, 29:330–336, 2007.
58.
TschöpM, WeyerC, TataranniPA, DevanarayanV, RavussinE, HeimanML: Circulating ghrelin levels are decreased in human obesity. Diabetes, 50:707–709, 2001.
59.
Weber–HamannB, KratzschJ, KopfD, LederbogenF, GillesM, HeuserI, DeuschleM: Resistin and adiponectin in major depression: The association with free cortisol and effects of antidepressant treatment. J Psychiatr Res, 41:344–350, 2007.
60.
WolfA M, WolfD, RumpoldH, EnrichB, TilgH: Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1 RA in human leukocytes. Biochem Biophys Res Commun, 323:630–635, 2004.
61.
ZarounaS, WozniakG, PapachristouAI: Mood disorders: A potential link between ghrelin and leptin on human body?. World J Exp Med, 5:103–109, 2015.
